For the year ending 2025-12-31, PVCT made $336,108 in revenue. -$5,430,851 in net income. Net profit margin of -1615.81%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Grant revenue | 336,108 | 617,140 | ||
| Research and development | 1,897,276 | 1,999,127 | ||
| General and administrative | 3,733,597 | 3,150,397 | ||
| Total operating expenses | 5,630,873 | 5,149,524 | ||
| Total operating loss | -5,294,765 | -4,532,384 | ||
| Interest expense | -210,359 | -239,073 | ||
| Research and development tax credit | - | 9,320 | ||
| Total other income (expense), net | -210,359 | -229,753 | ||
| Net loss | -5,505,124 | -4,762,137 | ||
| Net loss attributable to noncontrolling interest | -74,273 | -29,585 | ||
| Net loss attributable to common stockholders | -5,430,851 | -4,732,552 | ||
| Basic EPS | -0.01 | -0.01 | ||
| Diluted EPS | -0.01 | -0.01 | ||
| Basic Average Shares | 420,279,879 | 419,810,059 | ||
| Diluted Average Shares | 420,279,879 | 419,810,059 | ||
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)